Haloperidol Can Cause Hyponatremia, Though It Is Uncommon
Yes, haloperidol can cause hyponatremia through the syndrome of inappropriate antidiuretic hormone secretion (SIADH), though this is a rare adverse effect. While the FDA drug label does not explicitly list hyponatremia as a side effect 1, multiple case reports and research studies have documented this association 2, 3, 4.
Evidence for the Association
The mechanism involves haloperidol-induced SIADH, which has been documented in case reports dating back to 1979. In one well-documented case, a patient developed clinically significant hyponatremia on two separate occasions while receiving haloperidol, with documented inability to excrete a water load while on the medication and normal ability in its absence 2. Another case series confirmed SIADH development with both haloperidol and quetiapine, which resolved when switched to clozapine 3.
The risk appears highest during the first 2-4 weeks of treatment initiation 3, 5. A comprehensive review of psychotropic medication-induced hyponatremia identified several key risk factors:
- Advanced age (particularly elderly patients)
- Female gender
- Polypharmacy (concurrent use of other medications)
- Medical comorbidities
Importantly, the dosage of haloperidol does not appear to correlate with hyponatremia risk 5.
Clinical Context and Comparative Risk
Among antipsychotics, a large pharmacovigilance study using the FDA Adverse Event Reporting System found that dopamine D3 receptor occupancy was positively associated with hyponatremia risk (adjusted OR = 1.21), while serotonin 5-HT2A receptor occupancy showed a protective effect (adjusted OR = 0.78) 6. This suggests that typical antipsychotics like haloperidol, which have higher D3 occupancy and lower 5-HT2A occupancy compared to atypical antipsychotics, may carry a relatively higher risk profile for hyponatremia.
However, it's worth noting that SIADH can occur with many medications commonly used in cancer patients, including chemotherapeutic agents (platinum-based chemotherapy, vinca alkaloids), opioids, NSAIDs, anticonvulsants, and antidepressants 7. The 2018 ESMO guidelines specifically recommend discontinuing implicated medications, implementing fluid restriction, and ensuring adequate oral salt intake for confirmed SIADH 7.
Monitoring Recommendations
For patients starting haloperidol, particularly those with risk factors (elderly, female, polypharmacy, comorbidities), monitor serum sodium during the first 2-4 weeks of treatment 3, 5. The 2019 AGS Beers Criteria does not specifically list haloperidol as causing hyponatremia, though it does caution about tramadol in this context 8.
Clinical Presentation
Hyponatremia can manifest as:
- Confusion
- Agitation
- Lethargy
- Weakness
Any change in mental status during haloperidol treatment should prompt immediate sodium level assessment 5.
Management Approach
If hyponatremia develops:
- Assess severity and exclude other causes (adrenal insufficiency, hypothyroidism) 7
- Consider discontinuing haloperidol if SIADH is confirmed
- Implement fluid restriction (typically 500 mL/day initially, adjusted based on sodium levels)
- Ensure adequate oral salt intake
- For symptomatic or severe hyponatremia (sodium <120-125 mmol/L), more aggressive treatment with hypertonic saline may be warranted 9, 10
Important Caveat
In palliative care settings with short prognosis, strict fluid restriction may not align with patient goals of care and should be individualized 7.
The bottom line: While haloperidol-induced hyponatremia is uncommon, clinicians should maintain awareness of this potential complication, particularly during treatment initiation in high-risk patients, and monitor accordingly.